Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Targeted IL-13 Rα2 or B7-H3 UCAR-T in Advanced Glioma
NCT05752877Phase 1Recruiting
- Sponsor
- The Second Affiliated Hospital of Soochow University
- Start
- May 2021
- Primary completion
- Apr 2026
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of IL-13 Rα2 UCAR-T and MT027 CAR-T cells in glioma, sponsored by The Second Affiliated Hospital of Soochow University. Primary endpoint: Objective Response Rate up to 5 years. Started May 2021; status: recruiting.
02
Drugs
IL-13 Rα2 UCAR-TMT027 CAR-T cells
03
Conditions
glioma
Beyond the preview
Go deeper on NCT05752877.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05752877.